<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=All_The_Up-To-Date_Guidelines_On_Everolimus</id>
		<title>All The Up-To-Date Guidelines On Everolimus - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=All_The_Up-To-Date_Guidelines_On_Everolimus"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=All_The_Up-To-Date_Guidelines_On_Everolimus&amp;action=history"/>
		<updated>2026-04-19T06:02:12Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=All_The_Up-To-Date_Guidelines_On_Everolimus&amp;diff=144833&amp;oldid=prev</id>
		<title>Curleregypt6: Створена сторінка: e., with curative intent), no difference in outcome between EM and BM relapses was observed (median survival 13.5 vs 8 months for EM?vs?BM relapses, respectivel...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=All_The_Up-To-Date_Guidelines_On_Everolimus&amp;diff=144833&amp;oldid=prev"/>
				<updated>2017-02-24T06:57:44Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: e., with curative intent), no difference in outcome between EM and BM relapses was observed (median survival 13.5 vs 8 months for EM?vs?BM relapses, respectivel...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;e., with curative intent), no difference in outcome between EM and BM relapses was observed (median survival 13.5 vs 8 months for EM?vs?BM relapses, respectively, P?=?0.44). Our results suggest that EM relapse post-HSCT has similar outcomes to BM relapses treated in a similar way. Furthermore, choice of [http://www.selleckchem.com/products/PD-0332991.html Palbociclib in vitro] therapy at relapse appears related to the time post-HSCT that the relapse occurs, with BM relapses occurring significantly earlier post-HSCT than relapses at EM sites. &amp;quot;&amp;quot;Aim:? The aim of this study was to investigate the expression of telomere repeat binding factor 1 (TRF1), TRF2 and protection of telomeres 1 (POT1) in gastric cancer and their relationships with clinicopathological features and telomerase activity. Methods:? In total 36 gastric cancer tissue and paired adjacent normal tissue were analyzed. The mRNA expression of telomere binding proteins [http://www.selleckchem.com/products/Everolimus(RAD001).html Everolimus price] TRF1, TRF2 and POT1 were measured using quantitative reverse transcription polymerase chain reaction, and telomerase activity was assessed by the telomeric repeat amplification protocol/enzyme linked immunosorbent assay method. Results:? The expression of POT1 was significantly higher in tumor tissue than in adjacent normal tissue (P?[https://en.wikipedia.org/wiki/Cilengitide Cilengitide] tumor stage (P?=?0.008). A higher level of expression of POT1 was observed in late-stage tumors (III, IV) than in early stage tumors (I, II). Telomerase activity was significantly higher in gastric cancers than in corresponding normal tissue (P?&lt;/div&gt;</summary>
		<author><name>Curleregypt6</name></author>	</entry>

	</feed>